123 related articles for article (PubMed ID: 3742449)
41. Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group.
Eisenhauer EA; Silver HK; Venner PM; Thirlwell MP; Weinerman B; Coppin CM
Br J Cancer; 1987 May; 55(5):541-2. PubMed ID: 3606945
[No Abstract] [Full Text] [Related]
42. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
Sarna G; Figlin R; Callaghan M
J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
[TBL] [Abstract][Full Text] [Related]
43. Interferon therapy for renal cell carcinoma.
Muss HB
Semin Oncol; 1987 Jun; 14(2 Suppl 2):36-42. PubMed ID: 3589703
[TBL] [Abstract][Full Text] [Related]
44. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma.
Kuzmits R; Kokoschka EM; Micksche M; Ludwig H; Flener R
Oncology; 1985; 42 Suppl 1():26-32. PubMed ID: 4080298
[TBL] [Abstract][Full Text] [Related]
45. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
Muss HB; Costanzi JJ; Leavitt R; Williams RD; Kempf RA; Pollard R; Ozer H; Zekan PJ; Grunberg SM; Mitchell MS
J Clin Oncol; 1987 Feb; 5(2):286-91. PubMed ID: 3543247
[TBL] [Abstract][Full Text] [Related]
46. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
47. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
Kinouchi T; Meguro N; Maeda O; Saiki S; Kuroda M; Usami M; Kotake T
Int J Urol; 1996 Jan; 3(1 Suppl):S41-3. PubMed ID: 24304021
[TBL] [Abstract][Full Text] [Related]
48. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
49. [A study of the clinical response of renal cell carcinoma to human lymphoblastoid interferon (MOR-22)].
Niijima T
Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1277-84. PubMed ID: 3782978
[No Abstract] [Full Text] [Related]
50. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
51. [Combination therapy of renal cell carcinoma with interferon-alpha and UFT (or FT-207)].
Kobayashi M; Imai K; Yamanaka H; Takahashi H; Mashimo T; Shimizu N; Koya J; Yajima H; Kawashima K; Kitaura K
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1437-46. PubMed ID: 2509605
[TBL] [Abstract][Full Text] [Related]
52. [A cooperative phase I-II study of HLBI in patients with malignant tumors].
Kimura K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1324-31. PubMed ID: 6329104
[TBL] [Abstract][Full Text] [Related]
53. [A case of pulmonary metastasis from renal cell carcinoma in which complete remission was achieved by interferon therapy (r-IFN-alpha A, Ro 22-8181)].
Ishito N; Wada F; Aramaki K; Asano S; Johsen T
Gan To Kagaku Ryoho; 1986 Feb; 13(2):380-3. PubMed ID: 3947113
[TBL] [Abstract][Full Text] [Related]
54. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Quesada JR; Rios A; Swanson D; Trown P; Gutterman JU
J Clin Oncol; 1985 Nov; 3(11):1522-8. PubMed ID: 4056843
[TBL] [Abstract][Full Text] [Related]
57. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma.
Cancer; 1987 Sep; 60(5):929-33. PubMed ID: 3111677
[TBL] [Abstract][Full Text] [Related]
59. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
60. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
Vugrin D; Hood L; Laszlo J
J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
